Sucampo Presentats Results on Lubiprostone in Pediatric Functional Constipation at NASPGHAN 2013
October 11, 2013 at 05:58 AM EDT
Sucampo Pharmaceuticals (NASDAQ: SCMP ) announced Thursday the presentation of results from a Phase 3, open-label safety and efficacy study of lubiprostone in patients with pediatric functional constipation. These results demonstrate that lubiprostone increased spontaneous bowel movement (SBM) frequency and was well-tolerated in subgroups of children and adolescents with
